Brief: Caplin Point Laboratories Gets USFDA Approval For Brimonidine Tartrate, Timolol Maleate
26/02/2025 05:39
Feb 26 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS: CAPLIN POINT LABORATORIES - GETS USFDA APPROVAL FOR BRIMONIDINE TARTRATE, TIMOLOL MALEATE CAPLIN POINT LABORATORIES - UNIT GETS US FDA NOD FOR GLAUCOMA DRUGS Source text: ID:nBSE4ZXxt5 Further company coverage: CAPL.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees